Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 5/20 | 0.59 |
| ▸ | CSNK1G2 | P78368 | 4/20 | 0.59 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.59 |
| ▸ | GSK3B | P49841 | 3/20 | 0.59 |
| ▸ | CFB | P00751 | 9/20 | 0.56 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.52 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.52 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13677328 | 0.87 | CSNK1D (0.46) | CSNK1DCSNK1G2CSNK1A1GSK3BCFB | |
| SCHEMBL21822330 | 0.84 | PIN1 (0.54) | CSNK1DCSNK1G2CSNK1A1GSK3BCFB | |
| SCHEMBL7655150 | 0.84 | ALDH1A1 (0.58) | CSNK1DCSNK1G2CSNK1A1GSK3BCFB | |
| SCHEMBL3269719 | 0.80 | ALDH1A1 (0.58) | PIN1ALDH1A1SMN1; SMN2L3MBTL1METAP2 | |
| SCHEMBL12430878 | 0.78 | CSNK1D (0.61) | CSNK1DCSNK1G2CSNK1A1GSK3BCFB | |
| SCHEMBL29439000 | 0.78 | CSNK1D (0.61) | CSNK1DCSNK1G2CSNK1A1GSK3BCFB | |
| SCHEMBL846652 | 0.76 | SCN10A (0.78) | CSNK1DCSNK1G2CSNK1A1GSK3BALDH1A1 | |
| SCHEMBL18659837 | 0.75 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2L3MBTL1KCNH2SCN10A | |
| SCHEMBL22219469 | 0.75 | PIN1 (0.58) | CSNK1DCSNK1G2CSNK1A1GSK3BCFB | |
| SCHEMBL1245514 | 0.75 | PIN1 (0.58) | CSNK1DCSNK1G2CSNK1A1GSK3BCFB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | CSNK1D 1932/4885CSNK1G2 1718/4885CSNK1A1 1021/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | CSNK1D 1932/4885CSNK1G2 1718/4885CSNK1A1 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.